JP2012509273A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509273A5
JP2012509273A5 JP2011536585A JP2011536585A JP2012509273A5 JP 2012509273 A5 JP2012509273 A5 JP 2012509273A5 JP 2011536585 A JP2011536585 A JP 2011536585A JP 2011536585 A JP2011536585 A JP 2011536585A JP 2012509273 A5 JP2012509273 A5 JP 2012509273A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
nhc
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2011536585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/064730 external-priority patent/WO2010057160A1/en
Publication of JP2012509273A publication Critical patent/JP2012509273A/ja
Publication of JP2012509273A5 publication Critical patent/JP2012509273A5/ja
Ceased legal-status Critical Current

Links

JP2011536585A 2008-11-17 2009-11-17 核酸送達系のための放出可能融合性脂質 Ceased JP2012509273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11537808P 2008-11-17 2008-11-17
US61/115,378 2008-11-17
PCT/US2009/064730 WO2010057160A1 (en) 2008-11-17 2009-11-17 Releasable fusogenic lipids for nucleic acids delivery systems

Publications (2)

Publication Number Publication Date
JP2012509273A JP2012509273A (ja) 2012-04-19
JP2012509273A5 true JP2012509273A5 (enExample) 2012-12-27

Family

ID=42170408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536585A Ceased JP2012509273A (ja) 2008-11-17 2009-11-17 核酸送達系のための放出可能融合性脂質

Country Status (7)

Country Link
US (1) US20110223257A1 (enExample)
EP (1) EP2355799A4 (enExample)
JP (1) JP2012509273A (enExample)
CN (1) CN102215820A (enExample)
CA (1) CA2742846A1 (enExample)
TW (1) TW201021852A (enExample)
WO (1) WO2010057160A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
TW201021853A (en) * 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable cationic lipids for nucleic acids delivery systems
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
KR20190039347A (ko) * 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
JP5860874B2 (ja) 2010-06-22 2016-02-16 デエヌア・テラプーティックDnatherapeutics 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化invivo送達システム
ME03353B (me) * 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
WO2013086354A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US10358680B2 (en) * 2012-09-11 2019-07-23 Duke University Nano-plasmonic molecular probes for plasmonics coupling interference
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
ES2966631T3 (es) 2013-06-19 2024-04-23 Univ California Estructuras químicas para el suministro localizado de agentes terapéuticos
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
CN106659796B (zh) * 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
TWI665192B (zh) 2014-05-28 2019-07-11 德商拜耳作物科學股份有限公司 製備二氫異唑衍生物之方法
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2017044983A1 (en) 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
CN107951862B (zh) * 2016-10-17 2021-03-12 南京绿叶制药有限公司 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
AU2018250312C1 (en) 2017-04-07 2024-08-22 Tambo, Inc. Bioorthogonal compositions
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
CN117105811B (zh) * 2017-11-06 2025-12-12 日东电工株式会社 用于递送生物活性分子的膜融合化合物
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
LU103379B1 (en) * 2024-09-09 2026-03-09 Re3B Therapeutics Ug I G Serum-Protein Coated Fusogenic Lipid Particles For Targeted Drug Delivery

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
AU733310C (en) * 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6841537B1 (en) * 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US7015349B2 (en) * 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
EP1664316B1 (en) * 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
EP1692107A4 (en) * 2003-12-10 2008-10-29 Nitromed Inc NITROGEN OXIDE-RELATED PYRUVATE COMPOUNDS, COMPOSITIONS AND USE METHOD
US20060051405A1 (en) * 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
EP1845944A4 (en) * 2005-02-08 2011-07-27 Id Biomedical Corp Of Quebec C O B As Glaxosmithkline Biolog North America PHARMACEUTICAL COMPOSITIONS
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007086881A2 (en) * 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
JP2008533016A (ja) * 2005-03-07 2008-08-21 アイディー バイオメディカル コーポレイション オブ ケベック シー.オー.ビー. アズ グラクソスミスクライン バイオロジカルズ ノース アメリカ 薬学的リポソーム組成物
EP1996607A4 (en) * 2006-02-01 2009-06-24 Burnham Inst Medical Research LYMPH ADDRESS CODES FOR TUMORS AND PREMALARY LESIONS
US20070293449A1 (en) * 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
HUE040417T2 (hu) * 2007-05-04 2019-03-28 Marina Biotech Inc Aminosavlipidek és alkalmazásuk

Similar Documents

Publication Publication Date Title
JP2012509273A5 (enExample)
JP2012509272A5 (enExample)
JP2012509366A5 (enExample)
JP2025181861A5 (enExample)
CN113993839B (zh) 一种可离子化脂质分子、其制备方法及其在制备脂质纳米颗粒中的应用
JP2011529912A5 (enExample)
JP2012509258A5 (enExample)
CA2767129C (en) Compositions and methods for silencing apolipoprotein b
US9211343B2 (en) siRNA conjugate and preparation method thereof
EP2796150B1 (en) Novel oligonucleotide conjugates and use thereof
RU2018113459A (ru) Фармацевтическая композиция, содержащая анионное лекарственное средство, и способ ее получения
KR101752812B1 (ko) 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법
JP2012509066A5 (enExample)
KR101862349B1 (ko) 개선된 고효율 나노입자형 올리고뉴클레오타이드 구조체 및 그의 제조방법
CA2963271A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
AU2016201913A1 (en) Compositions and methods for silencing aldehyde dehydrogenase
WO2007056861A1 (en) Sirna silencing of influenza virus gene expression
US9035039B2 (en) Compositions and methods for silencing SMAD4
RU2016103695A (ru) СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ
KR101241852B1 (ko) siRNA 접합체 및 그 제조방법
KR20120119212A (ko) siRNA 접합체 및 그 제조방법
JP6051758B2 (ja) ジアシルグリセロールと結合した分岐型ポリエチレングリコール、その製造方法およびポリエチレングリコール修飾リポソーム
Kim et al. Antiviral efficacy of a short PNA targeting microRNA-122 using galactosylated cationic liposome as a carrier for the delivery of the PNA-DNA hybrid to hepatocytes
CN120398741A (zh) 一种用于递送核酸物质的脂肪酸衍生物及其合成方法
RU2020142571A (ru) Специфичные для гена амфирегулина двухцепочечные олигонуклеотиды и содержащие их композиции для профилактики и лечения связанных с фиброзом заболеваний и респираторных заболеваний